TNAP—a potential cytokine in the cerebral inflammation in spastic cerebral palsy

Xiaokun Wang, Chao Gao, He-Quan Zhong, Xiang‐Yu Kong, Rui Qiao, Hui-Chun Zhang, Bai-Yun Chen, Yang Gao, Bing LiFrontiers in Molecular Neuroscience 2022 · DOI

TL;DR

This study identifies Tissue-Nonspecific Alkaline Phosphatase (TNAP) as a key player in the neuroinflammation associated with spastic cerebral palsy (CP). By analyzing protein profiles in children with CP and using a rat model of hypoxic-ischemic encephalopathy (HIE), researchers found TNAP to be significantly downregulated in CP, suggesting it could be a novel therapeutic target.

What Problem Does This Paper Address?

Cerebral palsy (CP), a common neurological disorder in children, has an etiology that remains poorly understood, particularly for its most prevalent form, spastic CP (80% of cases). While neuroinflammation is recognized as a significant factor in CP's pathology, the specific molecular mechanisms and contributing factors are not fully elucidated. This paper aims to identify key molecular players involved in the neuroinflammatory processes of spastic CP to shed light on its pathogenesis and potentially uncover new diagnostic and therapeutic targets.

Methods

The researchers employed a multi-pronged approach:

  • Proteomics Profiling: They analyzed plasma samples from 18 children with spastic CP and 20 healthy controls using mass spectrometry-based proteomics to identify differentially expressed proteins.
  • Animal Modeling: A hypoxic-ischemic encephalopathy (HIE) model was established in postnatal day 7 rat pups to mimic CP. This model allowed for the investigation of behavioral deficits, as well as the measurement of inflammatory markers in both peripheral blood and brain tissue.
  • Biochemical Assays: Techniques like ELISA and Western blot were used to quantify the levels of specific proteins and inflammatory cytokines (e.g., TNAP, IL-6, IL-10, CRP, osteopontin, 25-hydroxyvitamin D) in both human and animal samples.
  • Behavioral Testing: The rat model underwent behavioral assessments, including righting reflex and balance beam tests, to evaluate motor function deficits.
  • Neuroimaging: Cranial MRI scans were performed on the human participants to characterize brain abnormalities.
  • Statistical Analysis: Standard statistical methods such as independent sample t-tests, ANOVA, and Pearson correlation were used to analyze the data.

Datasets

  • Human Plasma Samples: Collected from 18 children diagnosed with spastic CP and 20 age-matched healthy controls.
  • Rat Brain and Plasma Samples: Obtained from a hypoxic-ischemic encephalopathy (HIE) rat model and sham-operated controls at different time points post-induction.
  • Cranial MRI Scans: Acquired from the 18 children with spastic CP.

Key Insights and Ideas

  • TNAP as a Potential Biomarker: The consistent downregulation of TNAP in both human CP patients and the animal model strongly suggests its involvement in the disease process and its potential as a diagnostic marker.
  • Inflammation- and Vitamin D-Related Dysregulation: The study highlights a complex interplay between inflammation (increased CRP, IL-6, IL-17, osteopontin) and reduced levels of vitamin D (25(OH)D) in spastic CP, suggesting a broader metabolic and immune dysregulation.
  • TNAP's Role in Neuroinflammation Regulation: The findings point towards TNAP's critical role in modulating neuroinflammatory pathways, potentially by inhibiting NF-κB activation, a key player in inflammatory responses.
  • Translational Relevance: The successful correlation between TNAP levels in peripheral blood and brain tissue in the animal model strengthens the idea that peripheral measurements can reflect central nervous system changes.

Key Results

  • TNAP Downregulation: Proteomic analysis revealed that Tissue-Nonspecific Alkaline Phosphatase (TNAP), encoded by the ALPL gene, was significantly downregulated in the plasma of children with spastic CP compared to controls. This was further validated in the HIE rat model.
  • Inflammatory Marker Increase: In spastic CP patients and the HIE model rats, levels of pro-inflammatory biomarkers like C-reactive protein (CRP), IL-6, and IL-17 were elevated, while anti-inflammatory cytokine IL-10 and vitamin D (25(OH)D) were decreased. Osteopontin (OPN) was also found to be increased.
  • Behavioral Deficits in Model: The HIE rat model exhibited impaired motor function, evidenced by longer righting reflex times, increased time to cross a balance beam, and a higher frequency of leg slips.
  • Correlations: Serum TNAP levels showed a positive correlation with CRP and IL-10 in the model rats.
  • MRI Findings: A significant proportion of children with spastic CP showed abnormalities on cranial MRI, with periventricular leukomalacia (PVL) being the most common finding.

Limitations and Future Work

  • Limited Sample Size: The study involved a relatively small number of human participants (18 CP patients and 20 controls).
  • Animal Model Specificity: While the HIE model is widely used, it may not fully capture the complexity of human CP.
  • ALPL Knockdown Models: The authors note the lack of ALPL knockdown mice as a limitation and suggest that evaluating inflammatory reactions and molecular mechanisms in such models would be beneficial for future research.
  • Further Mechanistic Studies: The authors propose to investigate the molecular mechanisms by which TNAP regulates pro-inflammatory factors related to CP neuroinflammation in future studies. They also suggest exploring the effect of regulating TNAP expression on CP symptoms in animal models.

Summary updated

Abstract

Objective: Several studies have shown the significance of neuroinflammation in the pathological progress of cerebral palsy (CP). However, the etiology of CP remains poorly understood. Spastic CP is the most common form of CP, comprising 80% of all cases. Therefore, identifying the specific factors may serve to understand the etiology of spastic CP. Our research aimed to find some relevant factors through protein profiling, screening, and validation to help understand the pathogenesis of cerebral palsy. Materials and methods: In the current study, related clinical parameters were assessed in 18 children with spastic CP along with 20 healthy individuals of the same age. Blood samples of the spastic CP children and controls were analyzed with proteomics profiling to detect differentially expressed proteins. On the other hand, after hypoxic-ischemic encephalopathy (HIE) was induced in the postnatal day 7 rat pups, behavioral tests were performed followed by detection of the differentially expressed markers and inflammatory cytokines in the peripheral blood and cerebral cortex of the CP model rats by Elisa and Western blot. Independent sample t -tests, one-way analysis of variance, and the Pearson correlation were used for statistical analysis. Results: Through proteomic analysis, differentially expressed proteins were identified. Among them, tissue-nonspecific alkaline phosphatase (TNAP), the gene expression product of alkaline phosphatase (ALPL) , was downregulated in spastic CP. In addition, significantly lower TNAP levels were found in the children with CP and model rats. In contrast, compared with the sham rats, the model rats demonstrated a significant increase in osteopontin and proinflammatory biomarkers in both the plasma and cerebral cortex on the ischemic side whereas serum 25 hydroxyvitamin D and IL-10 were significantly decreased. Moreover, serum TNAP level was positively correlated with serum CRP and IL-10 in model rats. Conclusion: These results suggest that TNAP is the potential molecule playing a specific and critical role in the neuroinflammation in spastic CP, which may provide a promising target for the diagnosis and treatment of spastic CP.
BibTeX
@inproceedings{wang2022tnapa,
  author = {Xiaokun Wang and Chao Gao and He-Quan Zhong and Xiang‐Yu Kong and Rui Qiao and Hui-Chun Zhang and Bai-Yun Chen and Yang Gao and Bing Li},
  title = {{TNAP—a potential cytokine in the cerebral inflammation in spastic cerebral palsy}},
  booktitle = {Frontiers in Molecular Neuroscience},
  year = {2022},
  doi = {10.3389/fnmol.2022.926791},
}
Figure